Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LogicBio Therapeutics, Inc.

https://www.logicbio.com/

Latest From LogicBio Therapeutics, Inc.

VectivBio Grabs Tail Of Comet Therapeutics In New Rare Disease Play

Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.

Deals Rare Diseases

Stock Watch: Not So Fast, Gene Editors

Intellia’s announcement of the first in vitro gene editing proof of principle sent shockwaves through the life science investment space. But are there still many known unknowns.

Stock Watch Research & Development

Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio

US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.

Deals Business Strategies

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Transgenics
UsernamePublicRestriction

Register